Oncology biomarker clinical trial CAGR globally 2000-2018, by cancer type
This statistic depicts the compound annual growth rate (CAGR) of oncology biomarker clinical trials started worldwide between 2000 and 2018, by cancer type. During these years, brain/glioma/CNS cancer clinical trials had the highest CAGR of 25.1 percent, followed closely by lung cancer clinical trials with a CAGR of 24.9 percent.